Cargando…

Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease

There is a growing body of experimental and clinical evidence supporting mineralocorticoid receptor (MR) activation as a powerful mediator of renal damage in laboratory animals and humans. Multiple pathophysiological mechanisms are proposed, with the strongest evidence supporting aldosterone‐induced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spencer, Sarah, Wheeler‐Jones, Caroline, Elliott, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614124/ https://www.ncbi.nlm.nih.gov/pubmed/32128854 http://dx.doi.org/10.1111/jvp.12848

Ejemplares similares

The Kidneys and Aldosterone/Mineralocorticoid Receptor System in Salt-Sensitive Hypertension
por: Shibata, Shigeru, et al.
Publicado: (2011)

Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology
por: Funder, John W.
Publicado: (2017)

Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke
por: Dinh, Quynh N, et al.
Publicado: (2012)

Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone
por: Muñoz-Durango, N., et al.
Publicado: (2015)

Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
por: Gorini, Stefania, et al.
Publicado: (2019)

Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury
por: Luther, James M., et al.
Publicado: (2012)

Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology
por: Cannavo, Alessandro, et al.
Publicado: (2018)

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
por: Bamberg, Krister, et al.
Publicado: (2019)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
por: Yoshida, Yuichi, et al.
Publicado: (2021)

The Glucocorticoid Receptor is Required for Efficient Aldosterone-Induced Transcription by the Mineralocorticoid Receptor.
por: Johnson, Thomas A., et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2021)

Aldosterone nongenomically induces angiotensin II receptor dimerization in rat kidney: role of mineralocorticoid receptor and NADPH oxidase
por: Sinphitukkul, Kittisak, et al.
Publicado: (2019)

Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury
por: Nakamura, Toshifumi, et al.
Publicado: (2022)

Interaction of the Mineralocorticoid Receptor With RACK1 and Its Role in Aldosterone Signaling
por: Kuppusamy, Maniselvan, et al.
Publicado: (2017)

SAT-564 Effectiveness of Treatment with Mineralocorticoid Receptor Antagonistsin Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2020)

SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020)

Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats
por: Martín-Fernández, Beatriz, et al.
Publicado: (2016)

Aldosterone Rapidly Enhances Levels of the Striatin and Caveolin-1 Proteins in Rat Kidney: The Role of the Mineralocorticoid Receptor
por: Inthachart, Kevalin, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

FRI164 The Glucocorticoid Receptor is Required for Efficient Aldosterone-induced Transcription by the Mineralocorticoid Receptor
por: Johnson, Thomas A, et al.
Publicado: (2023)

Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor
por: Essick, Eric E., et al.
Publicado: (2011)

The Diuretic Torasemide Does Not Prevent Aldosterone-Mediated Mineralocorticoid Receptor Activation in Cardiomyocytes
por: Gravez, Basile, et al.
Publicado: (2013)

Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease
por: Gorini, Stefania, et al.
Publicado: (2018)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
por: Mai, Xurong, et al.
Publicado: (2022)

Urinary active transforming growth factor β in feline chronic kidney disease
por: Lawson, J.S., et al.
Publicado: (2016)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

The Aldosterone-Mineralocorticoid Receptor Pathway Exerts Anti-Inflammatory Effects in Endotoxin-Induced Uveitis
por: Bousquet, Elodie, et al.
Publicado: (2012)

Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
por: Lee, Jin Young, et al.
Publicado: (2021)

A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm Shift
por: Epstein, Murray
Publicado: (2022)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
por: Tesch, Greg H., et al.
Publicado: (2017)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease
por: Oka, Tatsufumi, et al.
Publicado: (2022)

Renal Senescence, Telomere Shortening and Nitrosative Stress in Feline Chronic Kidney Disease
por: Quimby, Jessica, et al.
Publicado: (2021)

Investigation of the transforming growth factor-beta 1 signalling pathway as a possible link between hyperphosphataemia and renal fibrosis in feline chronic kidney disease
por: Lawson, J.S., et al.
Publicado: (2021)

Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2018)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
por: Shi, Luo, et al.
Publicado: (2019)

Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and Dampers
por: Epstein, Murray
Publicado: (2021)

Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism
por: Lin, Yu-Fang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fmq4k8vou07pqudobsr6i33ue7